Clinical Trials in Sutton, United Kingdom
137 recruiting
Showing 1–20 of 199 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Lymphoma, T-CellLymphoma, B-Cell
Step Pharma, SAS180 enrolled15 locationsNCT05463263
Recruiting
Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled200 locationsNCT07195695
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled26 locationsNCT05800665
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled172 locationsNCT06824467
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 1Phase 2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC460 enrolled23 locationsNCT06843447
Recruiting
Phase 1Phase 2
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca177 enrolled52 locationsNCT07181161
Recruiting
Phase 1
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled7 locationsNCT06459869
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca450 enrolled100 locationsNCT04379596
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 1
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Advanced Solid Tumors
AstraZeneca40 enrolled11 locationsNCT07161414
Recruiting
Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
Novartis Pharmaceuticals940 enrolled70 locationsNCT06855277
Recruiting
Phase 1Phase 2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Bayer450 enrolled60 locationsNCT06914128
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled290 locationsNCT06252649
Recruiting
Phase 3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled147 locationsNCT05939414
Recruiting
Phase 3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Small Cell Lung Cancer ( SCLC )
Boehringer Ingelheim670 enrolled236 locationsNCT07472517